SCHEMBL14871018

SCHEMBL14871018

O=c1[nH]c(NP)nc2[nH]c3cccc(Cl)c3c12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.47
CHEK1 O14757 1/20 0.45
GRIN2D O15399 2/20 0.42
GRIN3B O60391 2/20 0.42
GRIN1 Q05586 2/20 0.42
GRIN2A Q12879 2/20 0.42
GRIN2B Q13224 2/20 0.42
GRIN2C Q14957 2/20 0.42
GRIN3A Q8TCU5 2/20 0.42
EGFR P00533 4/20 0.41
KDR P35968 4/20 0.41
TYMS P04818 4/20 0.40
ERCC5 P28715 1/20 0.40
FEN1 P39748 1/20 0.40
LCK P06239 2/20 0.39
SRC P12931 1/20 0.39
ZAP70 P43403 1/20 0.39
PDGFRB P09619 1/20 0.37
MAOB P27338 1/20 0.37
ADORA2A P29274 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30588970 0.79 TYMS (0.61) PARP1CHEK1GRIN2DGRIN3BGRIN1
SCHEMBL16509138 0.79 CHEK1 (0.46) PARP1CHEK1EGFRTYMS
SCHEMBL1367742 0.79 TYMS (0.61) PARP1CHEK1GRIN2DGRIN3BGRIN1
SCHEMBL1366483 0.78 PDGFRB (0.57) PARP1CHEK1GRIN2DGRIN3BGRIN1
SCHEMBL3110872 0.69 CHEK1 (0.55) PARP1CHEK1GRIN2DGRIN3BGRIN1
SCHEMBL29734052 0.69 CHEK1 (0.55) PARP1CHEK1GRIN2DGRIN3BGRIN1
Potassium SCHEMBL3642930 0.67 CHEK1 (0.54) PARP1CHEK1GRIN2DGRIN3BGRIN1
SCHEMBL3777833 0.67 CHEK1 (0.54) PARP1CHEK1GRIN2DGRIN3BGRIN1
SCHEMBL31619545 0.67 ERCC5 (0.53) CHEK1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL6009055 0.67 ERCC5 (0.53) CHEK1GRIN2DGRIN3BGRIN1GRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170246170-A1 Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof DUQUESNE UNIVERSITY OF THE HOLY SPIRIT 2017-08-31 US disclosed
US-9556198-B2 Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) 2017-01-31 US disclosed
US-20150232477-A1 Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof DUQUESNE UNIVERSITY OF THE HOLY SPIRIT 2015-08-20 US disclosed
US-9045489-B2 Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) 2015-06-02 US disclosed
US-20130096146-A1 Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof DUQUESNE UNIVERSITY OF THE HOLY SPIRIT 2013-04-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130096146-A1 Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof ABCG2, ABCC1, ABCB1 PARP1 375/4885CHEK1 120/4885GRIN2D 4485/4885
US-20150232477-A1 Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof ABCC1, ABCG2, TP53 PARP1 376/4885CHEK1 120/4885GRIN2D 4373/4885
US-20170246170-A1 Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof ABCC1, ABCG2, TP53 PARP1 376/4885CHEK1 120/4885GRIN2D 4373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.